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ABSTRACT 
 
Alzheimer's diseases (AD)   has been discovered and under research for more than 70 years, 
However there is no cure for these progressive and devastating diseases.  
Based on the following hypothsis: Aß metabolite problem/over production result in the 
accumulation, and lead to aggregation is the cause of Alzheimer’s disease. AApeptide and 
Melatonin derivatives can bind to Aß and block the aggregation of β amyloid monomers, decrease 
the toxicity of Aß to neurons and slow the progressive of Alzheimer’s diseases. In addition, 
AApeptide which mimic transmembrane peptide Tat will have similar transmembrane function.  
We have set up our goals as follows: 1) Using newly discovered peptidomimetics, 
AApeptides. We moved on to research to discover their potential of transmembrane activity and 
anti-Alzheimer's acitiviy. 2) In Addition, studies of small molecule melatonin derivatives were 
also progressed.  
Methods include in this research includes bioorganic synthesis, identification of 
spectroscopy and relative assays targeting on biological efficiency of Anti-Alzheimer’s diseases. 
The details of which will be described in Chapters.  
In conclusions, two sets of transmembrane peptidomimetics for drug transportation has 
been successfully evaluated and potential of AA peptide small molecules, melatonin derivatives 
are also evaluated.  
These works have gained good progress in research between AApeptide and Alzheimer’s 
Diseases. These works also established basis of research in developing peptidomimimetics as 
potential pharmacies against Alzheimer’s diseases.  
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CHAPTER 1:  
INTRODUCTION 
1.1 AApeptide and AD  
Alzheimer's diseases (AD)   has been discovered and under research for more than 70 
years,[1] However there is no cure for these progressive and devastating diseases. There are four 
major pathologies for Alzheimer's diseases: Tau phosphrylation[2], ApoE pathology[3], AchE 
activity pathology[1],   and  pathology of AD  Figure 1.1 shows the pathway of Aβ pathogenesis. 
 
Figure1.1 Aβ hypothesis of Alzheimer's diseases. 
In the light of newly discovered peptidomimetics, AApeptides. We moved on to the new 
era of research to discover their potential of transmembrane activity and anti-Alzheimer's acitiviy. 
Our study has shown that: 1) Our synthesized γ-AApeptide and α-AApeptide has comparable 
ability of transduction passing through the cell membrane; 2) AApeptide has potential as drug 
carrier for intracellular delivery, due to their character of both improved cellular translocation 
	 2 
efficiency and enhanced stability against proteolytic hydrolysis compared to AApeptides; 3) 
AApeptide which were identified by combinatory chemistry and antibody binding assay, has very 
good potential for the diagnosis and treatment of Alzheimer's diseases. 
 
 
Figure 1.2 Melatonin and Aβ hypothesis in Alzheimer's diseases. 
 
On the other hand, Melatonin has been long used as a small molecule pharmacy to regulate 
circadian syndrome. Recently, its great potential of anti-Alzheimer’s disease has been discovered 
and its mechanism has been studied,[4] such as tau pathology and anti-oxidative stress. However, 
its extracellular function, especially the interaction with pathological protein β-amyloid and 
melatonin receptor regulation in neuroblastoma cells, was rarely reported. Our data indicated that 
melatonin can prevent Aβ aggregation and then further prevent Aβ aggregation related cascade 
response.  Melatonin also helps cell clear out Aβ in mitochondria, and recover the function of 
mitochondria. The function of melatonin anti-aging or AD has been reported by several groups 
	 3 
and they are 1). This effect appears to be due to direct hydrophobic, residue-specific interactions 
between melatonin and Aβ, whereby melatonin disrupts imidazole-carboxylate salt bridges critical 
for Aβ fibrillar formation[5]; 2). melatonin has been shown to protect against Aβ-induced 
neurotoxicity in vitro and in vivo, most probably through its ability to affect antioxidant enzymes 
and to be a potent free radical scavenger/antioxidant against toxic oxygen- and nitrogen-based 
reactants[5]; However, its extracellular function, especially the interaction with pathological 
protein β-amyloid and regulation of melatonin receptor (MT1) was seldom reported. Herein, based 
on in vitro assays established, we would further discover the potential of melatonin derivatives in 
treating Alzheimer's Diseases.  
Our Hypothesis are: Aß metabolite problem/over production result in the accumulation, 
and lead to aggregation is the cause of Alzheimer’s disease. AApeptide and Melatonin derivatives 
can bind to Aß and block the aggregation of β amyloid monomers, decrease the toxicity of Aß to 
neurons and slow the progressive of Alzheimer’s diseases. In addition, AApeptide which mimic 
transmembrane peptide Tat will have similar transmembrane function.  
 
1.2 Outline of the Dissertation  
In this dissertation, we discuss the design, synthesis, and applications of AApeptide and 
Melatonin derivatives in Alzheimer's diseases and their future applications. 
In chapter 2, 3, we outline the study of membrane translocation of AApeptide which can 
be used as a future drug-delivery system. There toxicity are also evaluated.  
In chapter 4, we describe the development of AApeptide library via combinatory chemistry 
and their research in Alzheimer's diseases including anti-aggregation effect, anti-toxicity effect 
against Aβ fibrils.  
In chapter 5, melatonin derivatives are introduced. Their effect of Anti-Alzheimer's 
diseases are discussed. The effect on MT receptors are also evaluated in this section.  
In chapter 6, we summarize the major findings of this dissertation and then conclude with 
the future directions of this research. 
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CHAPTER 2: 
CELLULAR TRANSLOCATION OF a γ-AAPEPTIDE MIMETIC OF TAT PEPTIDE 
 
Note to Reader 
 This chapter has been previously published and has been reproduced by permission of 
Molecular Pharmaceutics. Original citation: Mol. Pharmaceutics 2012, 9, 1529−1534, Youhong 
Niu, Ge Bai, Haifan Wu et. al. 
 
2.1 Introduction 
 The therapeutic values of a wide variety of polypeptides and oligonucleotides have been 
limited by their poor biomembrane permeability until the discovery of cell penetration peptides 
(CPPs). These short peptides facilitate the transport of hydrophobic/hydrophilic macromolecules 
into the cytoplasm and nucleus of living cells without disrupting membranes.1 Among all available 
CPPs, the most eminent is the transcriptional activator (Tat) protein for human immunodeficiency 
virus, type 1 (HIV-1), and is composed of 86−102 amino acids.1,2 Detailed structure−function 
analysis reveals that the sequence responsible for the cellular uptake and nuclear localization of 
Tat is amino acids 49−57 (RKKRRQRRR) in the basic region.1−3 Further analysis of this short 
sequence indicated that the peptide backbone as well as the cationic charges brought by arginines 
contributes substantially to Tat’s uptake. Truncation of the peptide or substitution of the arginines 
with other cationic amino acids resulted in diminished cellular uptake. 
 
 The cellular-uptake mechanism of Tat still remains elusive, as both a passive transfer 
across the plasma membrane and an endocytic entry have been observed.1,4 In the earlier 2000s, 
Gellman et al.4 demonstrated using fluorescence confocal microscopy that the fluorescein-labeled 
Tat47−57 achieved cell entry through an energy-dependent and endosome-mediated system which 
was inhibited by sodium azide.4 Under endosome acidification, the peptide can then escape 
endosomal compartmentalization into the cytosol.4 In practice, numerous biologically active 
	 6 
proteins have been tethered to Tat and successfully delivered into intact cells. These proteins 
include the E2 repressor protein,5 apoptosis-promoting caspase-3 protein,6 CDK4/6 inhibiting 
peptide,7and ovalbumin.8 Additionally, in vivo studies with Tat-fused β-galactosidase displayed 
an ability for the chimera to transduct to all tissues in mice, including the brain.9 Despite the 
promising data accumulated from translocation studies, CPPs including Tat were found to undergo 
rapid degradation in biofluids, severely limiting most practical and/or clinical applications.10 
Though relatively more stable than other CPPs, Tat47−57 still suffered from a short half-life in 
epithelial cells (9 h in Calu-3 cells).10 In the past decade, peptidomimetics consisting of unnatural 
amino acids have been under extensive evaluation. These molecules comprise interesting 
biological activities by adopting protein-like secondary structures while, importantly, harboring 
resistance to proteolytic degradation. A number of peptidomimetics have been developed for 
cellular translocation purposes.3,4,11−13 Umezawa et al.11 constructed a β-amino acid analogue of 
Tat47−57 and showed that its cellular delivery efficiency was comparable to that of Tat47−57 at 
4 °C, albeit a bit weaker at 37 °C.11 A peptoid-based cationic N-hxg9 was also developed and 
showed favorable cellular uptake.3 Nonetheless, the application of peptidomimetics is still 
hindered, and partially hampered by the limits of available frameworks.14,15 Hence the exploration 
of new peptide mimics bearing novel framework and improved/increased functionalities and 
stability is currently of urgent need. 
 
 In an effort to identify new peptidomimetics with novel framework, we recently developed 
a new class of peptide mimics termed “γ-AApeptides”. γ-AApeptides were derived from γ-chiral 
PNAs, which are composed of γ-substituted Nacylated-N-amino-ethyl amino acids. They can 
either retain the functions of mimicked peptide or serve as potential inhibitors of protein/protein 
and protein/nucleic acid interactions.16,17 For example, γ-AApeptide bearing the functionalities of 
the helical domain of p53 demonstrated effective inhibition of the p53/MDM2 interaction,16 while 
γ-AApeptide mimicking Tat48−57 exhibited similar binding affinity to TAR RNAs of HIV.17 
Remarkably, γ-AApeptides are highly stable to proteases,16 thereby eliciting significant 
advantages over their natural counterparts for future biological applications. Since a comparable 
RNA binding activity was observed for the γ-AApeptide mimicking Tat48−57,17 it is essential to 
evaluate whether this γ-AApeptide can mimic the cellular translocation activity that Tat48−57 
features. Herein we demonstrate for the first time that a fluorescent γ-AApeptide mimetic of 
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Tat48−57 can efficiently translocate to cytoplasm and nucleus of cells with cell permeation ability 
comparable to or better than that of Tat48−57 at all concentrations tested.  
 
 
2.2 Experimental Section 
 
 
Figure 2.1 The structures of oligomers used in the experiments: Tat48−57 (Fl-GRKKRRQRRR) 
1, γ-AApeptide 2 (mimetic of Tat 48−57), and γ-AApeptide 3 (mimetic of Tat 48−53). 
 
 Materials and Instrumentation: Fmoc protected α-amino acids and Knorr resin were 
obtained from Chem-Impex, International, Inc. All other reagents and solvents were provided by 
either Sigma-Aldrich or Fisher Scientific. NMR spectra of intermediates and γ-AApeptide building 
blocks were obtained on a Varian Inova 400. γ-AApeptide sequences were prepared on a Knorr 
resin in peptide synthesis vessels on a Burrell wrist-action shaker. The γ-AApeptides were 
analyzed and purified on a Waters HPLC installed with both analytical and preparative modules, 
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respectively, and the desired fractions were lyophilized using a Labconco lyophilizer. Molecular 
weights of γ-AApeptides were identified on a Bruker AutoFlex MALDI-TOF mass spectrometer. 
Fluorescent flow cytometry was performed using a Zeiss fluorescent imaging system. Cellular 
Uptake Assay by Fluorescent Flow Cytometry.3 The oligomers were each dissolved in PBS buffer 
(pH7.4), and their concentration was determined by UV−vis spectrometer at 490 nm (ε = 67,000, 
absorption of fluorescein). Jurkat cells (human T cell line) were used for cellular uptake 
experiments. Cells were seeded to a 96-well plate with 6 × 105 
cells per well. Different volumes of oligomer stock solution (2% FBS in PBS solution) and PBS 
buffer were added to the 96-well plate (combined total of 200 µL) and incubated for 10 min at 37 
°C. The cells were then centrifuged, and the cell pellet was washed with PBS buffer. Such process 
was repeated three times, then cells were resuspended in 0.02% propidium iodide in PBS Figure 
1. The structures of oligomers used in the experiments: Tat48−57 (Fl-GRKKRRQRRR) 1, γ-
AApeptide 2 (mimetic of Tat 48−57), and γ-AApeptide 3 (mimetic of Tat 48−53). 
  
 Molecular Pharmaceutics Brief Article 1530 dx.doi.org/10.1021/mp300070w | Mol. 
Pharmaceutics 2012, 9, 1529−1534 buffer, and analyzed by using fluorescent flow cytometry. The 
data presented are the mean fluorescent signal for the 5,000 cells collected. Confocal 
Microscopy.4,18 Chamber slides were polylysinecoated by applying 0.01% poly-L-lysine in PBS. 
160,000 HeLa cells were plated in 1 mL of DMEM with 10% FBS and 1% PSG onto one slot of 
a plate. Oligomers were diluted to 5 µM in 1 mL of appropriate DMEM in 1.5 mL microcentrifuge 
tubes. Media was aspirated from plates and replaced with 500µL of complete DMEM containing 
peptide. Cells were incubated at 37 °C for 25 min and then washed gently with 2 mL of PBS. 1 
mL of 4% PFA was added to all wells. The plate was covered, and cells were incubated at room 
temperature for 15 min, after which 10 µL of DAPI/mounting medium was added directly to cells 
in wells. The cells were extensively washed with PBS buffer and then imaged at 63× magnification 
in oil emersion. 
 
2.3 Results and Discussion 
 The synthesis of γ-AApeptides was carried out on Knorr resin, following the standard 
Fmoc manual solid-phase synthesis, with building blocks prepared as described previously.16,17 
Two fluorescent γ-AApeptides were synthesized, with one (2) mimicking the full length of 
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fluorescein-labeled Tat48−57, and the other (3) mimicking the truncated piece Tat48−53 (Figure 
2.1). Fluorescein-conjugated Tat48−57 1 was prepared as a positive control. These synthesized 
oligomers were labeled with fluorescein at their N-terminus in order to allow for cellular uptake 
studies via flow cytometry and confocal fluorescence microscopy. The oligomers were subjected 
to HPLC purifications, with their identities confirmed by MALDI MS analysis (Table S1 in the 
Supporting Information).  
 
Figure 2.2 FACS cellular uptake assay of Tat48−57 (Fl-GRKKRRQRRR) 1, γ-AApeptide 2 
(mimetic of Tat 48−57), and γ-AApeptide 3 (mimetic of Tat 48−53). Jurkat cells were incubated 
with different concentrations of oligomers for 10 min at 37 °C. The ratios shown in the figure are 
the ratios of FACS cellular uptake between 1 and 2. 
 
 Cellular uptake was then first evaluated by flow cytometry. Figure 2 shows the 
representative results of luorescent flow cytometry for oligomers 1−3 in Jurkat cells. Whereas γ-
AApeptide 2 (red bar) exhibited almost identical cellular uptake as Tat48−57 1 (black bar) when 
both peptides were incubated at a concentration of 12.5 µM for 10 in at 37 °C, γ-AApeptide 2 
generally resulted in a higher cellular uptake compared to 1, when both were administered at the 
same low concentrations. The more efficient intracellular translocation of 2 at low concentrations 
may result from the existence of tertiary amide bonds in γ-AApeptide backbone, consistent with 
previously reported cellular uptake of peptoids.3 The reason for the same fluorescent intensity of 
1 and 2, observed when both were at 12.5 µM, was not clear. It may be due to the saturation of cell 
	 10 
entry when both peptides were dosed at high concentrations. As a negative control, the truncated 
γ-AApeptide 3 (blue bar) almost did not exhibit cellular uptake, with little fluorescence detected 
when it was incubated with Jurkat cells at the concentrations of 0.39−3.13 µM. Even at the highest 
concentration of 12.5 µM, the fluorescence of 3 was only one-fifth of those from either 1 or 2. This 
observation was consistent with previous reports that arginines 55−57 of Tat were critical for 
translocation 3 and β-peptide with depletion of these arginines failed to have any cell penetration.11 
Taken together, the flow cytometry study demonstrated the membrane crossing ability of γ-
AApeptide 2, with efficiency at least comparable to that of Tat48−57 1 itself. 
 
Figure 2.3. Confocal images of HeLa cells treated with 5 µM of Tat48−57 (Fl-GRKKRRQRRR) 
peptide 1 (A), γ- AApeptide 2 (B), and γ-AApeptide 3 (C) for 25 min at 37 °C. 
 
 As further verification and to visually confirm the cellular uptake as well as to understand 
the cellular distribution of γ-AApeptide 2, confocal fluorescence microscopy images were 
obtained for all oligomers, utilizing 5 µM of each oligomer with HeLa cells at 37 °C for 25 min. 
As shown in Figure 3A, the control peptide Tat48−57 effectively penetrated the cell membrane 
and can be unambiguously detected in both punctate and diffuse patterns within the cytoplasm and 
nucleus. These observations are in accordance with previous reports,4 in which punctate structures 
represent a distribution consistent with endosome sequestration. Compared to Tat48−57, γ- 
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AApeptide 2, however, not only can translocate to cytoplasm and nucleus but also appears 
localized to the nucleolus (Figure 2.3B), thereby suggesting its future potential to deliver agents 
to specific nuclear regions. Noteworthy, a similar observation has been previously documented for 
a β-peptide majorly composed of arginines,4 suggesting that the mechanism of localization to 
nucleolus may be related to the unnatural backbones of γ- AApeptide and β-peptide. In addition, 
although dominated by a diffuse pattern of uptake, punctuate fluorescence was also present in the 
confocal images of γ-AApeptide 2, indicating that Figure 2. FACS cellular uptake assay of 
Tat48−57 (Fl-GRKKRRQRRR) 1, γ-AApeptide 2 (mimetic of Tat 48−57), and γ-AApeptide 3 
(mimetic of Tat 48−53). Jurkat cells were incubated with different concentrations of oligomers for 
10 min at 37 °C. The ratios shown in the figure are the ratios of FACS cellular uptake between 1 
and 2. Figure 3. Confocal images of HeLa cells treated with 5 µM of Tat48−57 (Fl-
GRKKRRQRRR) peptide 1 (A), γ- AApeptide 2 (B), and γ-AApeptide 3 (C) for 25 min at 37 °C. 
 
 The cellular uptake may also be endosome-mediated and energydependent (Figure 2.3B). 
Regarding the negative control, as expected, at the concentration of 5 µM, no cellular translocation 
of the truncated γ-AApeptide 3 was detected by confocal microscopy (Figure 2.3C), which was 
believed as a result of the removal of key arginine groups.3 Taken together, the confocal images 
are highly consistent with the uptake data obtained utilizing fluorescent flow cytometry. To begin 
to evaluate the mechanism of uptake, cells before the incubation with peptides were pretreated 
with 0.5% sodium azide that is considered as an energy poison and can block the endosome-uptake 
pathway. The corresponding confocal images manifested that both Tat48−57 1 (Figure 2.4A) and 
γ-AApeptide 2 (Figure 2.4B) bolished their cellular translocation capability and failed to cross cell 
membranes, with their results similar to the negative control γ-AApeptide 3 (Figure 2.4C). All 
together, these results further confirmed that γ-AApeptide 2 undergoes cellular translocation 
through energy-dependent endocytosis, in a way similar to natural Tat48−57 peptide 1. 
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 Figure 2.4. Confocal images of HeLa cells pretreated with NaN3, and then 5 µM Tat48−57 (Fl-
GRKKRRQRRR) peptide 1 (A),γ-AApeptide 2 (B), and γ-AApeptide 3 (C) for 25 min at 37 °C. 
 
 The endocytic uptake mechanisms of γ-AApeptide 2 were further investigated by 
incubating 2 with HeLa cells that had been pretreated with filipin or sucrose, respectively (Figure 
5). Tat48−57 peptide 1 was used as a control. It is well-known that both filipin and sucrose are 
endocytosis inhibitors.18 Filipin can bind to cholesterol and inhibit caveolae-mediated endocytosis; 
while sucrose can block clathrin recycling via clathrin-coated pit mechanisms due to the 
hyperosmolarity conditions generated by high sucrose concentrations. Consistent with previous 
research findings,19 our experiments show that the treatment of either filipin or sucrose 
dramatically decreased the uptake of Tat peptide 1 (Figures 2.5A and 2.5B), strongly suggesting 
the existence of caveolae and clathrin-mediated endocytic pathways during Tat peptide 1 cellular 
uptake. Interestingly, the same simultaneous caveolae and clathrin-mediated endocytic uptake 
mechanisms were also identified for the uptake of γ-AApeptide 2, since its uptake was also  
significantly inhibited upon pretreatment of filipin (Figure 2.5C) and sucrose (Figure 2.5D). The 
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results further support that the cellular uptake mechanisms of γ-AApeptide 2 are similar to those 
of Tat peptide 1. The toxicity of a molecular transporter has to be considered before its further 
development for in vivo applications. To assess the potential application of γ-AApeptide 2 as a 
molecular transporter, its toxicity against mammalian cells was evaluated and compared to that of 
Tat48−57 peptide 1 (Figure 2.6). Under current experimental conditions, peptide 1 did not show 
significant toxicity against both HeLa and Jurkat cells, consistent with the fact that it has been 
frequently used for molecular delivery. Surprisingly, although the toxicity of 2 is comparable to 
that of 1 against HeLa cells at higher concentrations, 2 is less toxic than 1 at lower concentrations 
(0.39−1.56 µM). Moreover, 2 is generally less toxic than 1 in Jurkat cells; especially at high 
concentrations (6.25 and 12.5 µM), it shows at least 10% lower cytotoxicity than Tat peptide 1. 
The overall less cytotoxicity shown by 2 may be due to its γ-AApeptide framework, which 
represents another advantage over natural peptides besides the already known superior stability. 
The results demonstrate that γ-AApeptide 2 has a strong potential for the further development of 
novel molecular transporters for intracellular delivery.  
 
2.4 Conclusion 
 In conclusion, our work demonstrates that, as a novel type of peptidomimetics, γ-
AApeptide not only can mimic Tat peptide’s binding with RNA17 but also possesses comparable 
cellular translocation ability to Tat peptide. The translocation activity of γ-AApeptide is somewhat 
even better at low concentrations, presumably due to its unnatural backbone where most of the 
guanidine side chains are appended to the nitrogens. Accordingly, an enhanced cellular uptake of 
polyguanidine peptoid derivative has been previously observed.3 Our findings in confocal 
microscopy are complementary to Potocky et al.,4 that peptidomimetics’ cellular uptake is through 
endocytosis, which is the same as Tat itself. In addition to the findings that 2 is comparable to or 
even less toxic than Tat peptide 1 against mammalian cells, γ-AApeptide based unnatural 
peptidomimetics are also extremely stable toward biodegradation, which, taken together, suggest 
that the Figure 4. Confocal images of HeLa cells pretreated with NaN3, and then 5 µM Tat48−57 
(Fl-GRKKRRQRRR) peptide 1 (A), γ-AApeptide 2 (B), and γ-AApeptide 3 (C) for 25 min at 37 
°C. Figure 5. Confocal images of HeLa cells pretreated with filipin or sucrose and then with 
oligomers 1 and 2. HeLa cells were pretreated with 3 µg/mL of filipin or 200 mM sucrose for 10 
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min, and then incubated with 5 µM Tat48−57(FI-GRKKRRQRRR) 1 (A and B) or γ-AApeptide 2 
(C and D).  
 
 
Figure 2.5 Confocal images of HeLa cells pretreated with filipin or sucrose and then with 
oligomers 1 and 2. HeLa cells were pretreated with 3 µg/mL of filipin or 200 mM sucrose for 10 
min, and then incubated with 5 µM Tat48−57(FI-GRKKRRQRRR) 1 (A and B) or γ- 
AApeptide 2 (C and D). 
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Figure 2.6 MTT assay for Tat48−57 (Fl-GRKKRRQRRR) peptide 1 and γ-AApeptide 2 against 
HeLa and Jurkat cells. 
 
 New cell penetration peptide mimic 2 can be an efficient and robust agent in cellular 
delivery. The specific targeting to the nucleolus by 2 is also expected to be exploited in the future 
to selectively deliver cargo to certain domains of the nucleus. For future work, the mechanism of 
nucleolus targeting needs to be further elucidated. Moreover, in the search for CPPs of enhanced 
cellular translocation, more derivatives of γ-AApeptide 2 can be constructed, for example, by 
increasing the length of backbone, by introducing more functional groups to side chains, or by 
optimizing the distance between backbone and functional groups, which can be easily achieved by 
the limitless potential of derivatization of γ-AApeptides.16,17 Delivery of different types of cargo 
by 2 is currently under investigation. 
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CHAPTER 3: 
CELLULAR UPTAKE OF AN α-AAPEPTIDE 
Note to Reader 
Reproduced from Ref. Organic & Biomolecular Chemistry Cite this: Org. Biomol. Chem., 
2012, 10, 1149. with permission from the Royal Society of Chemistry. 
 
3.1 Contents 
 
AA peptide can cross the cell membrane and function as vectors for intracellular delivery. 
Here we show that an α-AApeptide is able to penetrate the membranes of living cells from an 
extracellular environment and enter the endosome and cytoplasm of cells. The efficiency of the 
cellular uptake is comparable to a Tat peptide (48–57) of the same length and is unexpectedly 
superior to an a-peptide with identical functional groups. The mechanism of uptake is similar to 
that of the Tat peptide and is through endocytosis by an energy-dependent pathway. Due to the 
easy synthesis of the α-AApeptides, their resistance to proteolytic hydrolysis, and their low 
cytotoxicity, α-AApeptides represent a new class of transporters for the delivery of drugs.  
 
 The cytoplasm of living cells is surrounded by a thin layer of plasma membrane which 
separates cells from their surrounding environment and protects them from outside changes.1,2 The 
membrane further consists of a phospholipid bilayer which makes a hydrophobic interior that 
excludes the permeation of hydrophilic molecules.1,2 Substances that are hydrophilic but necessary 
for cell survival can only be selectively transported into cells through channels or pumps associated 
with the cell membrane.1,2 As a result, the inability of a large number of drugs to enter cellular 
compartments severely limits their therapeutic applications. Recently, a class of cell penetration 
peptides (CPPs), or alternatively called protein transduction domains (PTD), was discovered. 
These can be readily internalized by cells and thereby utilized to deliver hydrophilic 
macromolecules into the cytoplasm and nucleus.3 One of the first identified CPPs was the Tat 
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peptide which is currently the most commonly used transporting tool or cellular delivery. 
Comprised of 86–102 amino acids, Tat can bind to TAR RNA and then activate the transcription 
of the human immunodeficiency virus, type 1 (HIV-1).3,4 Among the Tat’s sequence, amino acids 
49–57 (RKKRRQRRR) were identified to be responsible for Tat’s cellular uptake and nuclear 
localization.3–5 A detailed structure and activity analysis of this short sequence revealed that the 
cationic charges aswell as the number of arginines are key to the peptide’s cellular translocation.5 
Using fluorescein labeling followed by confocal microscopy, Tat47–57 was observed to enter cells 
through endocytosis, and later, exit the endosomes following the endosomal acidification.6 The 
endosome-uptake process was ATP-dependent and can be blocked by the ATP inhibitor, sodium 
azide.6 To date, truncated Tat has been used as a carrier for the intracellular delivery of a wide 
variety of cargoes including small molecules,7 oligonucleotides,8 small interferenceRNA,9 
peptides,10 peptide nucleic acids,11 proteins,12–15 and nanoparticles.16 Despite their promising 
effects in cellular delivery, CPPs were, however, limited in clinical applications due to their 
peptide backbones that were vulnerable to biodegradation.17 Although considered relatively more 
stable, Tat47–57 still only has a short half-life (9–10 h) in most epithelial cells.17 Though the 
metabolism of CPP is needed for a final release of chemically ligated cargos, a balance is required 
to avoid premature cleavage during the delivery. Hence, development of peptidomimetics that 
mimic Tat’s ability of cellular transportation but have a higher stability represents a promising 
topic in chemical biology and attracts increasing attention in biomedical research.  
 
 Up to now, several  eptidomimetics of distinct frameworks have been reported. Both the b-
peptide based b-heptalysine and b-heptaarginine were able to cross cell membranes and localize 
in the cytoplasm and nucleus, with the b-heptaarginine internalized to a greater extent.18 In another 
example, b-peptide based b-(VRRVRRVRRVRR) entered cells by endocytosis and gradually 
translocated to the nucleus and the nucleolus.6 For a direct comparison, a b-amino acid analogue 
of Tat47–57 was also synthesized which displayed comparable cellular translocation to the original 
Tat47–57.19 Other than b-peptide, Wender et al.5 developed a 9-mer D-arginine as well as a class 
of polyguanidine peptoid derivatives which all exhibited greatly enhanced uptake compared to 
Tat49–57. Nevertheless, in a very recent report, an oligomer of b-turn dipeptide mimics that was 
neither polycationic nor amphipathic turned out to be successfully internalized by cells to 
lysosomes.20 In spite of the progress made so far, the development of peptidomimetics is still 
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necessary21,22 and the search for peptidomimetics of new frames becomes crucial to facilitate the 
development of cellular transductible agents. In our case, we have recently proposed a new class 
of oligomers termed “α-AApeptides” since they are based on N-acylated-N-aminoethyl amino 
acids. The α-AApeptides, which, compared to traditional a-peptides, are resistant to protease 
degradation and can be limitlessly derivatized at their secondary amines.23,24 Herein, we show that 
in our exploration of potential applications of α-AApeptides, a a-AApoly (KR mimic) repeat was 
found to result in an unexpectedly higher cellular-uptake than the natural Tat48–57 peptide. 
Coupled with their facile solid phase synthesis and enhanced stability, α-AApeptides may 
represent a new type of transporter for the delivery of therapeutic agents. A cellular permeable α-
AApeptide was designed based on the notion that cationic residues such as lysine and arginine 
play substantial roles in an oligomers’ uptake.5,18 Given that polylysine or polyarginine based 
peptidomimetics have been well studied,5,6,18 we prepared a α-AApeptide 2 (Fig. 1) with side 
chains composed of functional groups identical to alternated lysine and arginine instead. Oligomer 
2 was the same length as natural Tat48–57 peptide, and can be readily synthesized following the 
standard Fmoc solid phase synthesis, with a α-AApeptide building block 5 which bore an extra N-
acetylated lysine-like side chain in addition to a regular arginine. The preparation of 5 was carried 
out based on previously published procedures (Fig. 2).23,24 Briefly, Pbf protected arginine amino 
acid benzyl (Bzl) ester was reacted with Fmoc–amino ethyl aldehyde to form an intermediate 4, 
which possessed a secondary amino group that can be further acetylated with Boc–
NH(CH2)3COOH, followed by hydrogenation to give the desired building block 5. As controls, 
a-peptide Tat48–57 1 was also synthesized, together with a-peptide 3 that has identical functional 
groups as α-AApeptide 2 (Fig. 1). All three oligomers were modified with fluorescein at their N-
terminals to allow for the fluorescence-based detection of their cellular-uptake activities. To 
evaluate their ability to enter Jurkat cells, oligomers 1–3 at a series of concentrations were 
incubated with Jurkat cells for 10 min at 37 ◦C in completeDMEMsupplemented with 10% FBS, 
after which the cellular fluorescence was measured by fluorescent flow cytometry. As shown in 
Fig. 3, α-AApeptide 2 unexpectedly displayed better cell binding ability than the natural peptide 
Tat48–57 1 at all of the tested concentrations, evenwhen both oligomerswere administered at 12.5 
mM. The difference between 1 and 2 became more significantwhen bothwere used at a 
lowconcentration range, e.g. from 0.39 mM to 3.13 mM. The control α-peptide 3 had the same 
functional groups as α-AApeptide 2, yet its incubation with cells resulted in the lowest 
	 21 
fluorescence, indicating its poor cellular translocation. Taken together, the lysine–arginine 
alternated α-AApeptide oligomer 2 had comparable cellular-binding to Tat48–57 itself, which is 
also unexpectedly superior to its natural peptide counterpart 3. Early studies suggested the 
importance of the number of arginines to an oligomer's cross-membrane ability. For example, a 
detailed structure–activity study revealed that arginine homo-oligomers containing more than 
seven arginines can exhibit enhanced cellular translocation compared to Tat47–57.5 The theory 
was further supported by an independent report that an eight arginine containing b-peptide resulted 
in better cellular-uptake than Tat47–57.6 In our case, α-AApeptide oligomer Fig. 3.1 Chemical 
structures of fluorescein-labeled oligomers 1–3.  
 
Figure.3.1 Chemical structures of fluorescein-labeled oligomers 1–3. 
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 2 comprised of only five arginines, yet it has already shown a comparable translocation 
ability from extracellular milieu to cytoplasm, thereby suggesting the possible contribution from 
other cationic groups such as lysines. Moreover, given that the control oligomer 3 bears all cationic 
groups identical to 2 but failed to have significant cellular permeation, the exceptional 
cellular transduction ability of 2 should be not only due to the cationic charges, but also because 
of its peptidomimetic framework. In this regard, improved cellular translocation has been 
previously observed for oligomers of a diverse set of frameworks, such as the d-isomer and retro-
inverso isomer of Tat49–57,5 or a polyguanidine peptoid.5 The α-AApeptide framework reported 
here may thereby serve as a promising supplement to those existing ones. To gain more insight in 
to their internalization and intracellular distribution, the cellular uptake of oligomers 1–3 was 
additionally monitored by confocal microscopy. Similar to literature reports,6,19 Tat48–57 1 was 
found in both the cytoplasm and nucleus of HeLa cells, and in a diffused pattern out of nucleus 
(Fig. 3.4A). Some sporadic punctation is shown that presumably represents an endocytic vesicle’s 
remnants,6 which is in agreement with the reported observation that the Tat peptide enters cells 
through the endocytic uptake pathway.6 In the case of α-AApeptide oligomer 2, however, although 
some of it was found localized in the cytoplasm and nucleus, most oligomers still remained in 
endosomes, showing a characteristic punctate fluorescence (Fig. 4B). As a negative control, the a-
peptide 3 expectedly failed to display any cellular uptake (Fig. 4C) and this negative result is 
consistent with the forementioned observations in the flow cytometry studies. To further confirm 
that the ATP-dependent endosomal uptake mechanism was adopted by oligomers 1–2 for their 
cellular translocation, HeLa cells were pretreated with the energy poison—sodium azide,6 before 
the incubation with oligomers. As shown in the b column of Fig. 5, neither Tat48–57 1 nor α-
AApeptide 2 were detectable inside the cells treated with sodium azide, and their corresponding 
confocal images appeared similar to that of the negative control 3. These results firmly indicate 
that endocytosis is the cellular path for oligomers 1–2.  
 To gain an insight on the endocytic uptake mechanisms of α-AApeptide 2, HeLa cells were 
pretreated with filipin or sucrose and then incubated with oligomer 1 and 2, respectively (Fig. 3.6). 
Both filipin and sucrose are endocytosis inhibitors;25 filipin is known to inhibit caveolae-mediated 
endocytosis by binding to cholesterol, while high sucrose concentration generates hyperosmolarity 
conditions and blocks internalization and clathrin recycling via clathrin-coated pit mechanisms. 
Tat peptide 1 shows significantly decreased cellular uptake upon treatment with both endocytosis 
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inhibitors (Fig. 3.6A and 3.6B), indicating that Tat peptide 1 simultaneously uses both caveolae 
and clathrin-mediated endocytic pathways, which is consistent to the previous report.26 
Interestingly, the significant inhibition of cellular uptake for α-AApeptide 2 was only observed 
with the treatment of filipin (Fig. 3.6C). The treatment of sucrose appears to have no or minimal 
affect on the cellular uptake ofα-AApeptide 2.The results suggests that although the clathrin-
mediated endocytic pathway possibly exists in the cellular uptake of 2, α-AApeptide 2 mainly uses 
the caveolae-mediated endocytic pathway for cellular translocation.  
 
Figure. 3.2 Synthesis of the AApeptide building block 5. Pbf = 2,2,4,6,7-
pentamethyldihydrobenzofuran-5-sulfonyl. (a)1. Et2NH/CH3CN, 2 h; 2. Fmoc–amino ethyl 
aldehyde, NaBH3CN/CH3OH, overnight. (b)1. Boc–NH(CH2)3COOH, DhBtOH/DIC, overnight; 
2. Pd/C, H2, MeOH. 
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Figure. 3.3 Fluorescent flow cytometry of oligomers 1–3. Oligomers 1–3 at a series of 
concentrations from 0.4 mM to 12.5 mM were incubated with Jurkat cells at 37 ◦C for 10 min, and 
their cellular uptake was measured by fluorescent flow cytometry. The relative readings were 
normalized according to the highest mean fluorescence of oligomer 1 (at 12.5 mM), and were 
represented by bars. (black colored: oligomer 1, red colored: oligomer 2, blue colored: oligomer 
3). 
 
 
Figure. 3.4 Confocal images of HeLa cells treated with oligomers 1–3. HeLa cellswere 
incubatedwith 5 mMTat48–57 (FI-GRKKRRQRRR)1 (A), a-AA peptide 2 (B), peptide 3 (C) at 
37 ◦C for 25 min, and then further processed for confocal microscopy. For each subsection: a, 
DAPI channel (stains DNA in nucleus); b, FITS channel (fluorescence from oligomers 1–3); c, 
merged view. 
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Figure. 3.5  Confocal images of HeLa cells pretreated with sodium azide and then with oligomers 
1–3. HeLa cells were pretreated with 0.5% sodium azide for 30 min, and then incubated with 5 
mM Tat48–57 (FI-GRKKRRQRRR) 1 (A), a-AA peptide 2 (B), peptide 3 (C) at 37 ◦C for 25 min 
before confocal microscopy. For each subsection: a, DAPI channel (stains DNA in nucleus); b, 
FITS channel (fluorescence from oligomers 1–3); c,)merged view. 
 
 
Figure. 3.6  Confocal images of HeLa cells pretreated with filipin or sucrose and then with 
oligomers 1–2. HeLa cells were pretreated with 3 mg mL-1 of filipin or 200 mM sucrose for 10 
min, and then incubated with 5 mM Tat48–57 (FI-GRKKRRQRRR) 1 (A and B) or a-AApeptide 
2 (C and D). For each subsection: a, DAPI channel (stains DNA in nucleus); b, FITS channel 
(fluorescence from oligomers 1–2); c, merged view. 
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 Endosome acidification was believed to be an important factor for a cationic peptide's 
emission from endosomes, and a cationic b-peptide was previously shown successfully 
translocating from endosome to cytoplasm, under the mediation of endosome acidification.6 Given 
that a considerable amount of 2 is also found in the cytoplasm (columns b–c of Fig. 3.4B), it is 
conceivable that instead of being completely trapped inside endosomes, α-AApeptide 2 has a 
relatively slow kinetic escape. This behavior may be again attributed to its unique backbone 
structure, which is significantly different from traditional a- or b-peptides and could thereby 
compromise the effect of endosome acidification. The detailed mechanism, however, remains 
elusive. In another aspect, the long-term accumulation of 2 in endosomes may make it a potential 
molecular transporter for endosome-targeted drug delivery. Despite the general accepted rule that 
the endosomal escape is desired for drug delivery, the endosomal system has been long regarded 
as an essential site of signal transduction.27 Numerous activated receptors and signaling 
components stored in endosomes have been regarded as emerging targets for drugs in the treatment 
of psychiatric disorders,27 inflammation,27 pain,27 Alzheimer’s disease,27–29 and cancer.30,31 Most 
recently, novel cellular translocating agents, such as pH-sensitive nanoparticles32 and noncationic 
oligomers,20 were developed to specifically target the endocytic organelles. The toxicity of α-
AApeptide 2 against mammalian cells was also evaluated, in order to demonstrate their potential 
for the development of novel molecular transporters for in vivo applications. For comparison, the 
control Tat48–57 peptide 1was also tested (Fig. 3.7). Consistent with previous findings, peptide 1 
did not show significant toxicity against both HeLa (a1) and Jurkat cells (b1). Interestingly, 
although 2 displayed similar toxicity (a2) to 1 against HeLa cells, 2 is generally less toxic than 1 
at all concentrations when incubated with Jurkat cells (b2). These results suggest that α-AApeptide 
2 has great potential for molecular transportation development. With the recently developed α-
AApeptide frame, we unexpectedly found that a poly(lysine–arginine) oligomer has a cellular 
penetration efficiency comparable to the natural Tat peptide, butmuch better than its own a-peptide 
counterpart, thereby making itself a novel carrier for molecular transportation.Whereas this 
oligomer crosses membranes via endocytosis, in a way similar to that of the Tat peptide, it is 
mainly sequestered in endosomes, suggesting the potential of α-AApeptide based agents in 
endosome-targeted drug delivery. Given that previously reported a- or b-peptides are either 
cytoplasm or nucleus targeted, and that only noncationic oligomers and nanoparticles were shown 
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to remain in endosome, to our best knowledge, the α-AApeptide based oligomer introduced here 
is the first case of an endosome-targeted cationic peptidomimetic. The low cytotoxicity of the α-
AApeptides further supports their potential for molecular transporter development. For future 
studies, more detailed structure/function studies are needed, especially to identify the optimal 
backbone length and the optimal length of the guanidine/primary amino ended side-chains that 
may be crucial to further improve the oligomer's cellular uptake. Studies to deliver 
chemotherapeutic drugs to tumor cells by this oligomer are currently in progress. 
 
Fig. 3.7 MTT assay for the Tat48–57 (Fl-GRKKRRQRRR) peptide 1 and a-AApeptide 2 against 
HeLa and Jurkat cells. a1, HeLa cells treated with 1; a2, HeLa cells treated with 2; b1, Jurkat 
cells treated with 1; b2, Jurkat cells treated with 2. 
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CHAPTER 4: 
ONE-BEAD-ONE-COMPOUND (OBOC) γ-AAPEPTIDE LIBRARY AND 
THEIR ANTI-ALZHEIMERS EFFECT 
 
Note to Reader 
Reproduced from Ref. Organic & Biomolecular Chemistry Cite this: Org. Chemical 
Communications, 2014 50, 5206-5208. with permission from the Royal Society of Chemistry. 
 
4.1 Background 
One of the most important goals in modern chemical biology and biomedical sciences is to 
identify molecular ligands that recognize peptides or proteins of interest with high specificity and 
affinity.[6] Combinatorial chemistry is a powerful approach for ligand screening as it creates a 
diverse library of compounds, which provides unbiased opportunity for ligand identification when 
the structural information of targets are not available or not helpful in the rational design.[6] In 
fact, most bioactive molecules are identified through screening efforts.[7, 8] As peptides have 
favorable protein binding capabilities and well-established synthetic protocol, early efforts were 
dedicated to the identification of selective peptide ligands against a variety of targets.[9-12] 
Unnatural peptidomimetic ligand libraries are of significant interest recently, as these ligands 
contain unnatural backbones and therefore possess enormous structural diversity and enhanced 
stability against proteolysis. The examples of peptidomimetic ligands include peptoids,[6, 13-18] 
β-peptides,[19] and N-acylated polyamine,[20, 21] etc. However, except for peptoids, the 
applications of peptidomimetic ligand libraries are rare. 
γ-AApeptides are a new class of peptidomimetics developed in our lab very recently in 
order to advance the application of peptidomimetics in chemical biology and biomedical sciences 
(Figure 3.1a).[22-29] As they contain N-acylated-N-aminoethyl amino acid units (Figure 3.1a) 
derived from γ-PNAs,[30] they are termed “γ-AApeptides”.[25] Each unit (building block) of the 
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γ-AApeptide is comparable to a dipeptide residue in a canonical peptide. As such, γ-AApeptides 
essentially project an identical number of functional groups as conventional peptides of the same 
length. Half of the side chains of γ-AApeptides are chiral, which may impose conformational bias 
to the molecular ligands similar to conventional peptides, and presumably lead to the identification 
of ligands with improved specificity and affinity.[6] Since the other half of the side chains are 
introduced through acylation of the nitrogen on the backbone by carboxylic acids or acyl chlorides, 
there is virtually limitless potential of generating γ-AApeptide libraries with chemically diverse 
functional groups. Moreover, γ-AApeptides are highly resistant to proteolytic degradation,[25, 31] 
making them ideal candidates to be molecular probes or therapeutic candidates.  
To further expand the biological potential of γ-AApeptides, herein we report the 
development of γ-AApeptide OBOC library via the split-and-pool method. N-alloc protected γ-
AApeptide building blocks were used to prepare γ-AApeptides of diverse functional groups 
(Figure 3.1b and 3.1c).[32] 
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Figure 4.1. Synthesis of the γ-AApeptides. a, An α-peptide and a γ-AApeptide. b, the synthesis 
of γ-AApeptides. c, N-Alloc protected γ-AApeptide building blocks and acylating agents 
(carboxylic acids and acyl chlorides) used in the preparation of γ-AApeptide combinatorial ligand 
library. 
4.2 Results and Discussion 
To find out if MS/MS could be potentially used to solve the unknown γ-AApeptide 
structure, we analyzed the fragmentation pattern of one known γ-AApeptide to prove that MS/MS 
is capable of determining the sequences of γ-AApeptides. As shown in Figure 3.2, this γ-
AApeptide produces fragments in clear patterns and the sequence can be deduced unambiguously. 
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Figure 4.2. MS/MS analysis of a known γ-AApeptide. HCD fragmentation of a double charged 
precursor ion was performed at collision energy of 35.  
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Figure 4.3. Schematic representation of synthesizing OBOC γ-AApeptide library. 
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We then proceeded to the next step by establishing a one-bead-one-compound (OBOC) γ-
AApeptide library. The library was prepared by the split-and-pool method which produces beads 
with only one compound displayed on one bead (Figure 3.3).[9] A methionine residue was first 
attached to the TentaGel beads (160002, 150 µm, 520, 000 beads/g), which facilitates the cleavage 
from beads by CNBr treatment. [33] Then 4 N-alloc-protected γ-AApeptide building blocks and 5 
acylating agents (including carboxylic acids or acid chlorides) (Figure 3.1c) were used to generate 
the combinatorial library of 4-building-block γ-AApeptides (comparable to 8-mer peptides in 
length). In theory, this library would contain 4 x 5 x 4 x 5 x 4 x 5 x 4 x 6 = 192,000 compounds.  
To explore the potential of this γ-AApeptide library as an excellent source of 
protein/peptide ligands, the library was screened against the Aβ40 peptide, which is one of the 
major etiological factors for Alzheimer’s disease (AD) and plays a central role in the pathogenesis 
of AD.[34, 35] Although it is of high significance to quickly identify novel anti-Aβ aggregation 
inhibitors, there is no effective approach to achieve it.[36]  
We hypothesized that the γ-AApeptide library can be used to identify ligands that bind to 
Aβ, and their anti-aggregation efficiency can be determined by functional assay afterwards. As 
such, we incubated beads with the Aβ40 peptide, followed by the treatment of anti-Aβ antibody 
6E10 (Figure 4.4a).  Then anti-mouse IgG-dylight 549 conjugate was added. Dylight 549 produces 
strong orange fluorescence, in which region TentaGel beads have low background 
fluorescence.[33] Out of ~192,000 beads, two putative hits (approximately 0.001% hit rate) were 
identified and collected. The low rate may suggest the high selectivity of the library. One of the 
structures was identified by MS/MS unambiguously (Figure 4.5). This lead, designated as HW-
155-1, was re-synthesized on Rink-amide resin (Figure 4.4b). The hydrophobic core residues 16-
20 of the Aβ peptide, KLVFF, which inhibits Aβ aggregation both in vitro and in vivo,[37-40] was 
also synthesized and used for comparison. In addition, we also synthsized HW-C-9 which is a 
dimeric form of AApeptide following the synthesis scheme as Figure 4.4c.  
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Figure 4.4. Screening of the γ-AApeptide library. a, Schematic representation of the on-bead 
screening of the γ-AApeptide library against the Aβ40 peptide. The last picture was taken under a 
fluorescent microscope installed with a triple filter pass. Excitation is 550 nm and emission is 605 
nm. b, the identified γ-AApeptide from the on-bead screening (HW-155-1) and the control peptide 
KLVFF. 
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Figure 4.4 (continued) c) Synthesis scheme of dimeric AA-peptide. 
These two sequences were investigated for their capability to inhibit the aggregation of 
Aβ40 by ThT assay. Consistent to previous reports, KLVFF is a weak disruptor of Aβ aggregates. 
100 µM of KLVFF can only inhibit less than 50% of Aβ aggregation (Figure 4.6a). Surprisingly, 
1 µM of HW-155-1 already inhibits ~50% of Aβ aggregation (Figure 4.6b), indicating it is at least 
100-fold more potent than KLVFF. The similar inhibitory effect was observed even after 24 h 
(Figure 3.6c). As such, HW-155-1 is one of the most potent small molecules that disrupt the 
aggregation of Aβ1-40. 
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Figure 4.5. Structural identification of one hit by MS/MS analysis. HCD fragmentation was 
performed on a double charged precursor ion (587.8827) and the collision energy was set at 35. 
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Figure 4.6. ThT assay of compounds against Aβ40. a, the change of fluorescence in the first 2 h of 
incubation of KLVFF with Aβ40; b, the change of fluorescence in the first 2 h of incubation of 
HW-155-1 with Aβ40; c, the ratio of aggregation after 24 h. Aggregation control (100%) is set as 
the change of fluorescence of 2.5 µM Aβ40 in Tris (pH 7.5) buffer. The concentration of ThT is 5 
µM. Excitation: 440 nm; emission: 482 nm. 
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Figure 4.7  ThT assay of Dimer against Aβ40. the change of fluorescence in the first 2 h of 
incubation of HW-C-9 with Aβ40. 
The ability of HW-155-1 to prevent Aβ aggregation was further confirmed by TEM (Figure 
4.8a and 4.8b). In fact, HW-155-1 can even disassemble pre-formed Aβ fibrils (Figure 3.7c and 
3.7d). In our experiments, the Aβ fibrils were not seen after incubating HW-155-1 with Aβ40 
monomers (prevention of aggregation) and pre-formed Aβ40 aggregates (disassembling 
aggregation) for 24 h. 
We then examined the effect of HW-155-1 on the toxicity of Aβ aggregates towards N2a 
neuroblastoma cells. In this cellular assay, Aβ42 was chosen as Aβ42 aggregates are easier to form 
and are more toxic than Aβ40 aggregates towards neural cells.[38, 41] As shown in Figure 3.8, 
aggregated Aβ42 kills 30% of N2a cells after 24 h incubation. In contrast, addition of 0.5 equiv. of 
HW-155-1 already reduces the death of N2a cells caused by Aβ42 to 25%, while the presence of 1 
equiv. HW-155-1 virtually completely removes the toxicity of Aβ42 and eliminates the death of 
N2a cells. The capability of HW-155-1 to rescue these neuroblastoma cells suggests that HW-
155-1 may prevent the formation of Aβ aggregates and thus decrease the Aβ toxicities.  
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Figure 4.8  TEM images. Monomeric Aβ40 in the absence (a) and presence (b) of HW-155-1 after 
24 h; and pre-aggregated Aβ40 in the absence (c) and presence (d) of HW-155-1 after 24 h. bar = 
1 µM. Aβ40 is 2.5 µM and HW-155-1 is 5 µM. 
4.3 Results and Discussion of AApeptide Function 
4.3.1 Thioflavin T Assay 
Compounds in different concentrations in Tris buffer Saline (TBS, pH 7.5) containing 10 
µM ThT were added into a black 96 well plate (corning # 3721).  Aβ1-40 monomer was freshly 
thaw and used to make a stock solution in TBS with a concentration of 5 µM. Equal volume of Aβ 
solution was added into the 96 well plate (Final Aβ conc. = 2.5 µM). Time-dependent fluorescence 
change was monitored by a Synergy 2 plate reader at an excitation wavelength of 440 nm and 
emission at 482 nm. After 24 h, the fluorescence change was recorded. 100% aggregation is the 
fluorescence change of 2.5µM Aβ40 in TBS buffer containing 5 µM ThT. 
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4.3.2 Transmission Electron Microscopy (TEM) 
Aβ40 preparations were adsorbed onto 200-mesh copper grids for 1 hour (until it is dry), 
and then stained with 1% uranyl acetate for 20 sec. The excess fluid was removed and the grids 
were analyzed with FEI Morgagni 268D TEM operated at 60 kV. 
4.3.3  MTT Toxicity Assay 
In siliconized tubes, Aβ42 peptide of 10 µM (in F-12 medium) was pre-incubated with 0, 
0.5 and 1 equiv. of HW-155-1 γ-AApeptide, respectively. These solutions were incubated on a 
rotating shaker (Barnstead 400100) at 8 rpm in 37 oC for 24 h.  Meanwhile, N2a cells were plated 
in 96-well plates (10000 cells/well) with three replicates for 24 h at 37 oC. Then pre-aggregated 
mixtures were added into each well to make the final Aβ concentration 1 µM. The plate was 
incubated for another 24 h at 37 oC. Next, 10 µL MTT reagent was added to the cells.  The plate 
was incubated for 4 h at 37 oC. After the addition of 100 µL solublization solution (10% Triton-X 
100 in acidic Isopropanol (0.1N HCl)) and incubation for overnight, OD values were read at 575 
nm.  The final cell viability was calculated as: 
Cell viability % = (OD575-ODblank)/(ODctrl – ODblank) x 100%. ODctrl is the OD of the well 
containing cells only. ODblank is the OD of the blank well.  
4.3.4. AD Mouse Brain Taper Assay.  
 APP/PS1 AD mice model (>10 months) brain are collected and sliced by freezing 
microtome. After fixation, mice brain tissue are incubated with HW-C-9 at 25µM. Control group 
are also set up. Aβ plaque stain are later quantified by their density and area.  Results are show as 
Figure 4.10.  
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Figure 4.9. Detoxification of Aβ42 aggregates by HW-155-1. N2a cells were cultured with 1 µM 
of pre-aggregated Aβ42 in the absence/presence of HW-155-1 for 24 h. 
 
Figure 4.10 Treatment of HW-C-9 in mouse brain tissue. 
Control 
HW-C-9 
100% 
30% 
Control HW-C-9 
Treatment of AD 
mouse brain 
 Immunohistochemical staining assay. Left, Mouse 
brain tissue was incubated with/without 25 µM HW-C-
9 overnight and stained with antibodies. Right, 
quantification of the density and strength of stains. 
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4.4 Conclusions 
In summary, we have developed a new class of peptidomimetic combinatorial library that 
shows great promise to be a rich source of protein/peptide ligands. γ-AApeptides have the unique 
backbone that allows introduction of diverse functional groups with limitless potential. Their 
similarity in size and chirality to canonical peptides also confers favorable characteristics to bind 
and interact with other peptides and proteins. Our initial effort with this novel library has led to 
the identification of a lead small γ-AApeptide that is 100-fold more effective than KLVFF to 
prevent and even disassemble Aβ aggregation, and removes the toxicity of Aβ aggregates towards 
N2a neuroblastoma cells. Such a compound may be used as the potential molecular probe or 
therapeutic agent for the treatment of Alzheimer’s disease (AD). For dimeric AApeptide, it also 
showed up great potential in disensemble of Aβ aggregation, both in vitro(Figure 4.7) and ex-vivo 
(Figure 4.10). We are currently working on the development of new γ-AApeptide on-bead libraries 
with novel functional diversities so as to discover new bioactive candidates for biomedical 
applications, as well as the optimization of the lead γ-AApeptide HW-155-1 for the intervention 
of AD. 
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CHAPTER 5 
THE FUNCTION OF MELATONIN DERIVATIVES IN INHIBITING Aβ 
AGGREGATION AND APPLICATION IN AD PREVENTION 
 
5.1 Introduction 
 Alzheimer's diseases, which first discovered by Dr. Alzheimer's Alois in 1901, has become 
a well-recognized and very serious problem of society. However, even with great effort of the past 
50 years, the cure of AD has not been discovered until now.   
 Melatonin, N-acetyl-5-methoxytryptamine, has been long been used as a small molecule 
pharmacy to regulate circadian syndrome. Recently, its great potential of anti-Alzheimer’s disease 
has been discovered and mechanism has been studied,[4] e.g. anti-oxidative stress.  However, its 
extracellular function, especially the interaction with pathological protein Beta-amyloid and 
melatonin receptor regulation in neuroblastoma cells, was rarely reported. Our data indicated that 
melatonin can prevent Aβ aggregation and then further prevent Aβ aggregation related cascade 
response.  Melatonin also facilitate cellular clearance of Aβ in mitochondria, and recover the 
function of which. The function of melatonin anti-aging or AD has been reported by several groups 
and they are 1). This effect appears to be originated from direct hydrophobic, residue-specific 
interactions between melatonin and Aβ, whereby melatonin disrupts imidazole-carboxylate salt 
bridges critical for Aβ fibrillar formation[5]; 2). melatonin has been shown to protect against Aβ-
induced neurotoxicity in vitro and in vivo, most probably through its ability to affect antioxidant 
enzymes and to be a potent free radical scavenger/antioxidant against toxic oxygen- and nitrogen-
based reactants[5];  In this study, we used the solid phase synthesis to build up a library of small 
molecules derived from structure of melatonin.  
 It has been reported that, the risk of Alzheimer's diseases is closely related to Aging, 
especially at age of 62-65 years old, the onset of AD in patients is increased by more than 5 times 
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that of 40 years old. Meanwhile, the level of melatonin from pineal glands decreases with the aging 
process of patients. (Figure 5.1) Early to 1999, Pappolla, M. reported that melatonin, a hormone 
recently found to protect neurons against Abeta toxicity, interacts with Abeta1-40 and Abeta1-42 
and inhibits the progressive formation of beta-sheets and amyloid fibrils.  
 
Figure 5.1 Relationship between Age and Melatonin level in patients 
 In our previous studies, Melatonin suppresses Aβ aggregation into oligomers in vitro. (A) 
Western blots showing melatonins ability to decrease oligomeric Aβ when added to solutions of 
2.5 or 5 µg Ab1-42, which is then allowed to aggregate for 16 hr. Furthermore, it is recently 
reported by Dr. Cao’s lab, having effect of Anti-Aβ aggregation.  Binding of Melatonin to Aβ 
peptide has been reported in many papers. 
          In sum, based on the assumption that, structure of melatonin is closely related to its 
molecular biological function, we chose melatonin as an leading compound of our small molecule 
studies to discover new potential pharmacy for Alzheimer's diseases. In order to improve  the 
effeciency of melatonin derivatives, we have designed 4 pathways of modifications when building 
up our library,  in order to discover the structure-effectiveness relationships in between. 
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Figure 5.2 Anti-aggregation assay in Aβ aggregation. A) Aβ1-42 anti-aggregation assay 
with/without presence of melatonin. B) Aβ1-40 anti-aggregation assay with serial dilution 
of melatonin. Lane1: Aβ peptide monomer without aggregation. Lane2: negative Aβ 
aggreagtion control. Lane3: Aβ aggregation with 100 µM melatonin. Lane4: Aβ 
aggregation with 10 µM melatonin. Lane5: Aβ aggregation with 1 µM melatonin. 
 
5.2  Experimental Design 
5.2.1 Structures of Melatonin Derivatives 
The structure of the compounds are as follows: 
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Figure 5.3 Structures of melatonin derivatives. 
 
 The melatonin derivatives are synthesized by one-step reaction which method are 
described in detail in support information. (Figure S5.1) 
 
5.2.2 Toxicity Screening of Melatonin Derivatives in N2a APP Cells 
 Neuro2a cells with Amyloid β Precursor protein transgenic were incubated in 37 °C and 
split into 96 well plate after passage for at least 1-2 generations. 10000 cells/well of N2a APP 
cells are treated with series dilutions of melatonin derivatives. After incubation of 48 hours, 
the toxicity of compounds was evaluated by MTT assay. For cell culture assay and treatment 
of melatonin derivatives, please see support information. (S5.2) 
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Figure 5.4 Cell toxicity evaluation of melatonin derivatives. Serial dilution by 1:5 of melatonin 
derivatives from 1000-0.4 µM were treated to N2a APP cells. MTT assay were performed after 
incubation.  
 
5.3 Evaluation of Anti-Aggregation Effect 
 In vitro anti aggregation assay of Aß1-40and Aß1-42. HFIP pretreated Aβ 1-42 peptide 
was obtained from Biomer Techonology, California. Prepare Abeta1-42 peptide solution in 
Ham’s F-12 solution to  concentration of 200uM as stock.  In the 15ul aggregation system, 
add: 1) compounds at final concentration of 100, 10 or 1µM 2) 1.5µl peptide stock solution. 
Then make up to 15µl with F-12 medium. Aggregate for 48 hours at 37 °C.  Then followed by 
using the standard procedure to do western blotting. After membrane was developed, film with 
bands was scanned, followed by analysis of gel-quantification software (QuantityOne, from 
Bio-rad). 
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Figure 5.5 Anti-aggregation effect of  melatonin derivatives. Melatonin derivatives were 
incubated with Aβ peptide for 2- 16 hours, followed by Western Blot assay. A) M1;B) 
M2; C) M3; D) M4; E) M5.  
 
5.4 Regulation of Melatonin Receptors Induced by Melatonin Derivatives 
 Methods: Expression of Melatonin Receptors. N2a APP cells were plated in 6 well plates, 
treated with melatonin, then incubated for 36 hours before harvested. Save the supernatant, then 
RNA extraction was performed using RNA extraction kits from EZ Bioresearch. RNA 
quantification was followed using Nanodrop. Reverse transcription was followed using RT-PCR 
system from promega. Then PCR reaction was done with designed Primers Foward 
GAAACCCGACAACAAGCCCAAACT, Reverse TAACTAGCCACGAACAGCCACTCT. 
PCR products was analyzed by Argrose Electrophoresis and Gel quantification software. 
 
Figure 5.6 Melatonin receptor expression in N2a APP cells. The band value are 
quantified and calculated by their gray-scale value. 
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Table 5.1 Expression of Melatonin receptor in N2a APP cells. Band of MTRn1 are 
quantified by their gray-scale value(G) and calculated as follows: 
change% = [G(mel) - G(control)]/G(control)x 100% 
 
 
5.5 Data Analysis and Discussion  
 In sum, according to our design, there are four pathways of structural modification 
which are evaluated:1. Elongation of amide side chain with halogen. 2. Elongation of 
amide side chain with spaced bulky group. 3. Elongation of amide side chain with Alkyl 
groups.4. Dimerization of melatonin derivatives.  
 
Table 5.2 Summary of anti-aggregation effect.  
 
 
 
 
Positive 
(decrease 
aggregation)  
Negative 
(increase 
aggregation)  
No change 
N/A  M6, M9  M1, M2, M3, M4, 
M5, M7, M8, M10  
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3.1 Evaluation of anti-aggregation. In this section, among all modifications, we didn't 
discover any compounds with positive effects of anti-aggregation. (Figure 5.5) However, 
M6 and M9 are showing activity of promoting aggregation. (Table 5.2)  
3.2 Evaluation of MTR1 expression 1. For modification 1-3, no obvious corresponding 
change discovered in MT1R receptor regulation. Except for M1 and M6 which decreased 
the expressing of MTR in N2a APP cells, for dimerization (modification4), the activation 
of MT1R receptor was reversed. (Figure 5.7, Table 5.3)  
 
 
Figure 5.7 a) Modification 1 Elongation of amide side chain with ha  
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Figure 5.7 b) Modification 2 Elongation of amide side chain with spaced bulky group. 
 
Figure 5.7 c)Modification 3 Elongation of amide side chain with Alkyl groups 
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Figure 5.7 d) Modification 4 Dimerization of melatonin derivatives. 
 
Table 5.3 Summary of Melatonin Receptors Expression 
 
  
Positive 
(up-reguation)  
Negative 
(down-regulation)  
No change( not obvious) 
Melatonin, M2, M3, 
M7  
M1, M9, M10  M4, M5, M6, M9  
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5.6 Conclusions and Discussion 
 Melatonin has been reported in previous research which disrupt β-sheet structure of β-
amyloid protein. 6 However, according to the up-mentioned results.(Figure 4.10 and Table 5.2), 
none of the derivatives nor pathway of synthesis are giving promising results at molecular level. 
Which indicate that, melatonin, the small molecule hormone not only functions in AD as an β-
sheet breaker7, further their combined function such as mitochondrial protection, free radical 
scavenger and effect of adjusting circadian syndrome are benefiting Alzheimer's patients in an 
broad way.  
 Although, we didn’t find Melatonin Derivatives which prevent or disrupt aggregation of 
amyloid beta peptides, some derivatives we discovered M6, M9 has significant effect of promoting 
aggregation.(Table 5.2)  In 1993,  Mantyh PW, Ghilardi JR 8 reported that metal ions has effect of 
promoting aggregation of β-amyloid protein. Our results is prompting another set of small 
molecules which also have similar effect. Hence, the assessment of pro-aggregation effect will be 
very necessary for evaluating the risk of inducing AD for small molecule compounds, before they 
are entering clinical trial. Furthermore, compounds with good activity might be used for facilitating 
aggregation of Aβ protein, speeding up building progress of AD animal models.  
 In the study of MTR regulation, melatonin derivatives M2, M3 and M7 are showing 
regulatory effect of MTReceptor at the same direction. Since they are not as potent as melatonin, 
which are less likely to be elected as good MTR agonist. Some other melatonin derivatives 
showing down-regulation of MTR, can be applied to treat as company drug of melatonin, to limit 
the activation of melatonin-induced sleep through Melatonin receptor.  
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CHAPTER 6: 
 CONCLUSIONS AND FUTURE DIRECTIONS 
 
AA-peptide, as a novel generation of peptidomimetics, has shown great potential in drug delivery 
when mimicking the Tat peptide. And their potential of anti-Alzheimer's diseases has been 
evaluated. Which revealed bright future of moving on to in vivo mice study.  
Small molecules melatonin derivatives, according to our research, has slim potential in anti-
Alzheimer's. However, they have shown good value of application in promoting the aggregation 
for animal model design. Their potential of regulating MT receptors are also a worthwhile field 
for further research and discovery.  
AA-peptide screened by combinatory chemistry and antibody binding assay have very good 
potential of application as discussed above.  
In the future, we are planning to use the features of drug delivery in AA peptide, to conjugate with  
our  AA-peptide with Aβ breaker, facilitating them to pass through Blood brain barrier and 
obtaining better opportunity for further application in animal model and patients.  
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APPENDIX A:  
SUPPORTING INFORMATION 
Chapter 2 
S2.1 General experimental methods.  
 Fmoc protected γ-amino acids and Knorr resin were obtained from Chem-Impex 
International, Inc. All other reagents and solvents were provided by either Sigma-Aldrich or Fisher 
Scientific. NMR spectra of intermediates and γ-AApeptide building blocks were obtained on a 
Varian Inova 400. γ -AApeptide sequences were prepared on a Knorr resin in peptide synthesis 
vessels on a Burrell Wrist-Action shaker. The γ -AApeptides were analyzed and purified on a 
Waters HPLC with both analytical and preparative modules, respectively, and the desired fractions 
were lyophilized using a Labconco lyophilizer. Molecular weights of γ-AApeptides were 
identified on a Bruker AutoFlex MALDI-TOF mass spectrometer. Fluorescent flow cytometry was 
performed using a Zeiss fluorescent imaging system.  
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Figure S2.1 The structures of oligomers used in the experiments. 
 
S2.2 Solid phase synthesis, purification and characterization of  AApeptides.  
 The fluorescein conjugated Tat 48-57 peptide 1 was synthesized and analyzed by the USF 
peptide facility, and was used without further purification. γ-AApeptide building blocks were 
synthesized as reported previously. 1 The two γ-AApeptides 2 and 3 were prepared using a Knorr 
resin in peptide synthesis vessels on a Burrell Wrist-Action shaker following the standard Fmoc 
chemistry of solid phase peptide synthesis protocol. 1 Each coupling cycle included an Fmoc 
deprotection using 20% Piperidine in DMF, and 4 h coupling of 1.5 equiv of γ -AApeptide building 
blocks onto resin in the presence of 2 equiv of diisopropylcarbodiimide(DIC) / 
Oxohydroxybenzotriazole in DMF. After the desired sequences were assembled, they were 
transferred into a 4 mL vial and cleaved from solid support in 48:50:2 
TFA/CH2Cl2/triisopropylsilane overnight. Then solvent was evaporated and the residues were 
analyzed and purified on an analytical (1 mL/min) and a preparative Waters (20 mL/min) HPLC 
systems, respectively. The same methods were used by running 5% to 100% linear gradient of 
solvent B (0.1% TFA in acetonitrile) in solvent A (0.1% TFA in water) over 40 min, followed by 
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100% solvent B over 10 min. The desired fractions were >70% in crude (as determined by HPLC) 
and eluted as single peaks at > 95% purity, which were then collected and lyophilized. The 
molecular weights of γ-AApeptides and Tat peptide 1 were obtained on a Bruker AutoFlex 
MALDI-TOF mass spectrometer.   
 
 
Chapter 3 
S3.1. General experimental methods.  
 Fmoc protected a-amino acids and Knorr resin were obtained from Chem-Impex 
International, Inc. All other reagents and solvents were provided by either Sigma-Aldrich or Fisher 
Scientific. The NMR spectrum of the α-AApeptide building block 5 was obtained on a Varian 
Inova 400. The α-AApeptide sequence was prepared on a Knorr resin in peptide synthesis vessels 
on a Burrell Wrist-Action shaker. The α-AApeptide was analyzed and purified on a Waters HPLC 
with both analytical and preparative modules, respectively, and the desired fraction was 
lyophilized using a Labconco lyophilizer. Molecular weight of the α-AApeptide was identified on 
a Bruker AutoFlex MALDI-TOF mass spectrometer. Fluorescent flow cytometry was performed 
using a Zeiss fluorescent imaging system. 
S3.2. Solid phase synthesis, purification and characterization of α -AApeptides. 
 The fluorescein conjugated Tat 48-57 peptide 1 was synthesized and analyzed by the USF 
peptide facility, and was used without further purification. The γ-AApeptide building block 5 was 
synthesized as reported previously. 1, 2 The α-AApeptide 2 and the regular peptide 3 were prepared 
on a Knorr resin in peptide synthesis vessels on a Burrell Wrist-Action shaker following the 
standard Fmoc chemistry of solid phase peptide synthesis protocol. 1, 2 Each coupling cycle 
included an Fmoc deprotection using 20% Piperidine in DMF, and 4 h coupling of 1.5 equiv of 
building blocks onto resin in the presence of 2 equiv of diisopropylcarbodiimide(DIC) / 
Oxohydroxybenzotriazole in DMF. After the desired sequences were assembled, they were 
transferred into a 4 mL vial and cleaved from solid support in 48:50:2 
TFA/CH2Cl2/triisopropylsilane overnight. Then solvent was evaporated and the residues were 
analyzed and purified on an analytical (1 mL/min) and a preparative Waters (20 mL/min) HPLC 
systems, respectively. The same methods were used by running 5% to 100% linear gradient of 
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solvent B (0.1% TFA in acetonitrile) in solvent A (0.1% TFA in water) over 40 min, followed by 
100% solvent B over 10 min. The desired fractions were collected and lyophilized. The molecular 
weights of oligomers were obtained on a Bruker AutoFlex MALDI-TOF mass spectrometer using 
a–cyano-4-hydroxy-cinnamic acid 
as the matrix.  
 
 
Figure S3.1. The structures of oligomers used in the experiments. 
 
 
Table S3.1. MALDI-TOF MS analysis of AApeptides. 
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Figure S3.2 HPLC traces of oligomeric sequences 
 
S3.3. Cellular uptake assay by fluorescent flow cytometry. 3 
The oligomers 1, 2, 3 were each dissolved in PBS buffer (pH 7.4), and their concentration was 
determined by UV-vis spectrometer at 490 nm (ɛ = 67,000, absorption of fluorescein). Jurkat cells 
(human T cell line) were used for cellular uptake experiments. Cells were seeded to 96 well plate 
with 6 X 105 cells per well. Different volume of oligomer stock solution (2% FBS in PBS solution) 
and PBS buffer were added to the 96-well plate (combined total of 200 µl) and incubated for 10 
min at 37°C. The cells were then washed with PBS buffer for three times, and then analyzed by 
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using fluorescent flow cytometry and the data presented are the mean fluorescent signal for the 
5,000 cells collected. 
 
 
 
S3.4. Confocal Microscopy. 4, 5 
Co-localization studies. A cell plate (with 4 slots) was polylysine-coated by applying 0.01 % Poly-
L Lysine in PBS. 160,000 Hela cells were plated in 1mL of DMEM with 10% FBS and 1% PSG 
onto one 
slot of plate. Oligomers were diluted to 5 µM in 1mL of appropriate DMEM in 1.5 mL 
microcentrifuge tubes. Media was aspirated from plates and replaced with 500uL complete DMEM 
containing peptide. Cells were incubated at 37 oC for 25 minutes and then washed gently with 2 
mL PBS. 1mL of 4% PFA was added to all wells. Plate was covered and cells were incubated at 
room temperature for 15 minutes, after which 10 µL of DAPI/mounting medium was added 
directly to cells in wells. The cells were extensively washed with PBS buffer and then imaged at 
63 X magnification in oil emersion.  
Inhibition of Cellular Uptake with Sodium Azide. The assays were performed as described above 
with the exception that the cells used were pre-treated for 30 min with 0.5% sodium azide in 2% 
FBS/PBS buffer before the addition of oligomers, and then viewed by confocal microscopy. 
Inhibition of Cellular Uptake with filipin. The assays were performed as described above with 
the exception that the cells used were pre-treated for 10 min with 3µg/ml filipin in serum free 
DMEM medium before the addition of oligomers, and then viewed by confocal microscopy. 
Inhibition of Cellular Uptake with sucrose. The assays were performed as described above with 
the exception that the cells used were pre-treated for 10 min with 200 mM sucrose in serum free 
DMEM medium before the addition of oligomers, and then viewed by confocal microscopy.  
 
 
S3.5 MTT proliferation assay 
Jurkat cells (CRL-1990, ATCC) were cultured in RPMI 1640 media (containing 10% FBS and 
Penicillin and Streptomycin). After 12 hours before treatment, cells were separated by pipetting 
and plated in 96-well plate with ≈5,0000 cells in 100 µL media per well. Control and Blank wells 
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were prepared accordingly. Serial dilutions of oligomers at concentrations of 12.5, 6.25, 3.12, 1.56, 
0.78, 0.39 µM (50 µL per well at 2x concentration) were prepared by diluting stock solution with 
media. 50 µL media were removed from each well without disturbing Jurkat cells, which were 
loosely attached to the plate. Then 50uL diluted oligomer solutions (2x) were transferred to cells, 
resulting in a final 1x concentration for each well. After 36 hours, all media in cells was carefully 
removed. 10 µL MTT reagent (Roche) and 100 µL pre-warmed media were then added. The plate 
was incubated at 37°C for 4 h, to which was added 100 µL pre-warmed solubilization solutions 
each well. After overnight incubation, the absorbance of each well at 550nm was read and 
recorded. The data was processed based on the equation: Percentage of viability =[ (A − A 
bland)/(A control − A blank)] × 100%, where A is the average absorbance of the blank wells with 
only media and MTT solutions, and A control is the average absorbance of wells of cells without 
treatment of oligomers. The measurements were repeated at least three times. 
 
Hela cells were cultured in DMEM media (contain 10% FBS and Penicillin and Streptomycin). 
After 12 hours before treatment, cells were separated by pipetting and plated in 96-well plate with 
≈1,0000 cells in 100 µL media per well. Control and Blank wells were prepared accordingly. Serial 
dilutions of oligomers at concentrations of 12.5, 6.25, 3.12, 1.56, 0.78, 0.39 µM (100µL per well 
at 2x concentration) were prepared by diluting stock solution with media. All media in each well 
was removed. Then 50 µL media and 50 µL diluted oligomer solutions (2x) were transferred to 
cells, resulting in a final 1x concentration in each well. After 36 hours, all media in cells was 
carefully removed. 10 µL MTT reagent (Roche) and 100 µL pre-warmed media were then added. 
The plate was incubated at 37°C for 4 h, to which was added 100 µL pre-warmed solubilization 
solutions each well. After overnight incubation, the absorbance of each well at 550nm was read 
and recorded. The data was processed based on the equation: Percentage of viability =[ (A − A 
bland)/(A control − A blank)] × 100%, where A is the average absorbance of the blank wells with 
only media and MTT solutions, and A control is the average absorbance of wells of cells without 
treatment of oligomers. The measurements were repeated at least three times.  
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Chapter 4  
S4.1. Library synthesis 
S4.1.1 General information 
 All Fmoc protected α-amino acids and Rink amide resin (0.7 mmol/g, 200-400 mesh) were 
purchased from Chem-Impex International, Inc. TentaGel MB NH2 resin (0.3 mmol/g, 140-170 
µm) was purchased from RaPP Polymere GmbH. All the other solvents and reagents were 
purchased from either Sigma-Aldrich or Fisher Scientific. NMR data for building blocks was 
obtained on a Varian UnityInova400 spectrometer. High resolution masses of building blocks were 
determined on an Agilent 6540 Liquid Chromatography/Quadrupole Time-of Flight mass 
spectrometer. Masses of γ-AApeptides were obtained on an Applied Biosystems 4700 Proteomics 
Analyzer. MS/MS analysis was carried out with a Thermo LTQ Orbitrap XL. Solid phase synthesis 
was conducted in peptide synthesis vessels on a Burrell Wrist-Action shaker. γ-AApeptides were 
analyzed and purified on a Waters Breeze 2 HPLC system, and then lyophilized on a Labcono 
lyophilizer. 
S4.1.2.  Solid phase synthesis of γ-AApeptides 
 
Scheme S4.1. Solid phase γ-AApeptide synthesis 
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 Solid phase synthesis was conducted on Rink amide resin (0.7 mmol/g) in peptide synthesis vessels 
on a Burrell Wrist-Action shaker (Scheme S1). 100 mg resin (0.07 mmol) was treated with 3 mL 20% 
Piperidine/DMF solution for 15 min (× 2) to remove Fmoc protecting group. The solution was drained and 
beads were washed with DCM (3 × 3 mL) and DMF (3 × 3mL). A solution of γ-AApeptide 
building block (2 equiv.),1-5 HOBt (38 mg, 0.28 mmol), and DIC (44 µL, 0.28 mmol) in 3 mL 
DMF was shaken for 5 min, and then added to the resin in a peptide synthesis vessel. The mixture 
was allowed to react at room temperature for 6 h and drained. The beads were washed with DCM 
(3 × 3 mL) and DMF (3 × 3 mL), followed by a capping reaction with 500 µL acetic anhydride in 
3 mL Pyridine. After washing with DMF (3 × 3 mL) and DCM (3 × 3 mL), to the beads were 
added Pd(PPh3)4 (8 mg, 0.007 mmol) and Me2NH·BH3 (25 mg, 0.42 mmol) in 3 mL DCM. 6 
The alloc deprotection reaction was shaken for 10 min and repeated one more time. The beads 
were washed with DCM and DMF, followed by the reaction with acid chloride (4 equiv.) and 
DIPEA (6 equiv.) in 3 mL DCM for 30 min (× 2) or with carboxylic acid (4 equiv.), HOBt (8 
equiv.), and DIC (8 equiv.) for 4 h (× 2). 
 
 The previous steps were repeated until the desired sequences were obtained. After that, the 
resin were washed with DCM and dried in vacuo. Peptide cleavage was done in a 4 mL vial by 
treating resin with TFA/H2O/TIS (95/2.5/2.5) for 2 h. The solvent was evaporated and the crude 
was analyzed and purified on an analytical (1 mL/min) and a preparative (20 mL/min) Waters 
HPLC systems, respectively. 5% to 100% linear gradient of solvent B (0.1% TFA in acetonitrile) 
in A (0.1% TFA in water) over 40 min was used. The HPLC traces were detected at 215 nm. The 
products were confirmed on an Applied Biosystems 4700 Proteomics Analyzer. Then, the desired 
fractions were collected and lyophilized. 
 
S4.1.3. MS/MS analysis 
 The fragmentation pattern of a known γ-AApeptide was analyzed on a Thermo Scientific 
LTQ Orbitrap XL mass spectrometer (Figure S1). Higher Energy Collision Dissociation (HCD) 
was performed at collision energy of 35.  
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Figure S4.1. MS/MS analysis of a known γ-AApeptide. HCD fragmentation of a double charged precursor 
ion was performed at collision energy of 35. 
 
S4.1.4  Synthesis of the OBOC γ-AApeptide library 
 The TentaGel NH2 resin (1.6 g, 0.48 mmol, 832,000 beads) was swelled in DMF for 1h, 
followed by the treatment with Fmoc-Met-OH (3 equiv.), HOBt (6 equiv.), and DIC (6 equiv.) in 
DMF. 7 The beads were shaken at room temperature in a peptide synthesis vessel for 4 h and 
repeated. The beads were washed with DCM (× 3) and DMF (× 3). Fmoc protecting group was 
removed with 20% piperidine in DMF for 20 min (× 2). The beads were washed and equally 
distributed into four peptide synthesis vessels. Each building block (2 equiv.) together with HOBt 
(4 equiv.) and DIC (4 equiv.) were dissolved in DMF and added to each vessel. The coupling 
reaction was performed at room temperature for 6 h and repeated. The beads in each vessel were 
then washed and mixed thoroughly by severe shaking for 1 h. The beads were equally split into 
five vessels. The Alloc protecting group was removed by treating beads with Pd(PPh3)4 (0.1 equiv.) 
and Me2NH·BH3 (6 equiv.) in DCM for 10 min (× 2). After washing, each portion was reacted 
with either acid chloride or carboxylic acid. The reaction with acid chloride (5 equiv.) was carried 
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out in the presence of DIPEA (5 equiv.) and DCM for 30 min (× 2). The carboxylic acids (3 equiv.) 
were pre-activated with DIC (6 equiv.) and HOBt (6 equiv.) in DMF, then added to beads. The 
reaction was carried out by shaking the vessel for 6 hours and repeated. After that, all the beads 
were pooled and mixed thoroughly. The previous split-and-pool process was repeated three times. 
The last time, after attachment of building blocks, beads were equally distributed into six portions, 
five of which were treated with alloc deprotection reagents then with acid chlorides and carboxylic 
acids as shown previously. The sixth portion was kept unreacted. At last, all beads were combined 
in one peptide synthesis vessel and washed thoroughly with DMF and DCM. Beads were treated 
with 20% piperidine in DMF for 20 min (× 2) and then with TFA/TIS/H2O (95:2.5:2.5) for 2 h to 
remove all the protecting groups. The beads were washed with DCM thoroughly and dried in vacuo.  
 
Scheme S4.2. Schematic representation of synthesizing OBOC γ-AApeptide library. 
 
S4.2 Combinatorial Library Screening 
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S4.2.1. General information 
 The amyloid beta peptide Aβ40 was used as a target for the combinatorial library screen 
because insoluble Aβ plaque was thought to be a pathological marker in Alzheimer’s disease (AD). 
8 The synthesized library was stored in a glass peptide synthesis vessel, and later washed and 
incubated in the same container. The antibodies were purchased from Fisher Scientific, and all the 
other chemicals were provided by Sigma-Aldrich. The beads were screened and picked up under 
Zeiss inverted fluorescence microscope 10x43HE filter. 
 
S4.2.2. Beads screening 
 The library synthesized on TentaGel beads was swelled in dimethylformamide (DMF) for 
1 hour, washed with 1×TBST for five times and then equilibrated in 1×TBST overnight at room 
temperature. 9 The beads were blocked in 1% BSA in TBST for 1 hour, washed and equilibrated 
in 1×PBST before prescreening and screening. 
 Prescreening: In order to avoid any possible nonspecific binding, both the Aβ and 
antibodies solution were made in 1% BSA/TBST blocking buffer. The library was first incubated 
with mouse 6e10 primary antibody (200 ng/mL) which recognizes the first 16 amino acids of Aβ1-
40, followed by five times PBST wash and incubation with goat anti-mouse IgG conjugated with 
dylight 549 (200 ng/ml). The beads were washed with PBST completely and transferred into a 6-
well plate to be observed under Zeiss inverted fluorescence microscope 10×43HE filter, and the 
orange bright beads were picked up for they had suspicious nonspecific binding. These bright 
beads were excluded for further screening. 
 The rest of the beads were pooled together, washed with PBST, and then treated with 1% 
SDS at 90 oC for ten minutes to remove any bound proteins. We used both water and TBST to 
wash away the SDS and then the beads were washed and swelled in DMF for 1 hour. After washing 
and equilibrating in TBST overnight, the beads were ready for actual Aβ screening. 
Screening: The prescreened beads were equilibrated in 1% BSA/PBST for 1 hour at room 
temperature. Aβ solution was made by dissolving Aβ40 powder in the buffer right before the 
screening. After washing with PBST for three times, the beads were incubated with Aβ40 peptide 
at a concentration of 20 µg/mL for 4 h at room temperature. Since Aβ40 aggregates quite slowly 
and the screening was done in such as short time, the percentage of Aβ40 aggregation in the 
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solution was very minimal. After thorough washing with PBST, the library beads were incubated 
in 5 mL of 1% BSA/PBST containing 1:5000 diluted mouse 6e10 antibodies for 2 hours at room 
temperature. The beads were gently washed with PBST and incubated with 1:500 diluted goat anti-
mouse IgG-dylight 549 for 1 hour at room temperature. The beads were washed with PBST and 
transferred into the 6-well plate to be observed under Zeiss inverted fluorescence microscope 
10×43HE filter. Again the bright orange ones were picked up as candidates for further study. 
 
S4.2.3. Sequence decoding 
 The beads were collected and washed with 1×PBST three times. The bound fluorescent 
dyes, proteins, and antibodies were removed by treating beads with 1% SDS solution at 90 °C for 
10 min. After being washed with water, DMSO, and acetonitrile, beads were then cleaved and 
analyzed using previous procedure. The structure of one hit was determined (Figure S6) and 
designated as HW-155-1.  
 
 
Figure S4.2. Structural identification of one hit by MS/MS analysis. HCD fragmentation was  
performed on a double charged precursor ion (587.8827) and the collision energy was set at 35. 
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Figure S4.6. Pure HPLC trace of compound HW-155-1 (a) and KLVFF peptide (b). 
 
 
S4.3 Function bioassays 
 
S4.3.1. Thioflavin T assay  
 Compounds in different concentrations in Tris buffer Saline (TBS, pH 7.5) containing 10 
µM ThT were added into a black 96 well plate corning@3721. Aβ40 monomer was freshly thaw 
and used to make a stock solution in TBS with a concentration of 5 µM. Equal volume of Aβ 
solution was added into the 96 well plate (Final Aβ conc. = 2.5 µM). Time-dependant fluorescence 
change was monitored by a Synergy 2 plate reader at an excitation wavelength of 440 nm and 
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emission at 482 nm. After 24 h, the fluorescence change was recorded. 100% aggregation is the 
fluorescence change of 2.5 µM Aβ40 in TBS buffer containing 5 µM ThT. 
 
 
S4.3.2. Transmission electron microscopy (TEM) 
 Aβ40 preparations were adsorbed onto 200-mesh copper grids for 1 hour (until it is dry), 
and then stained with 1% uranyl acetate for 20 sec. The excess fluid was removed and the grids 
were analyzed with FEI Morgagni 268D TEM operated at 60 kV. 
 
S4.3.3. MTT toxicity assay 
 In siliconized tubes, Aβ42 peptide of 10 µM (in F-12 medium) was pre-incubated with 0, 
0.5 and 1 equiv. HW-155-1 γ-AApeptide, respectively. These solutions were incubated on rotating 
shaker (Barnstead 400100) at 8 rpm in 37 oC for 24 h. Meanwhile, N2a cells were plated in 96-
well plates (10000 cells/well) with three replicates for 24 h at 37 oC. Then pre-aggregated mixtures 
were added into each well to make the final Aβ concentration 1 µM. The plate was incubated for 
another 24 h at 37 oC. Next, 10 µL MTT reagent was added to the cells. The plate was incubated 
for 4 h at 37 oC. After the addition of 100 µL solublization solution (10% Triton-X 100 in acidic 
Isopropanol (0.1N HCl)) and incubation overnight, OD values were read at 575 nm. The final cell 
viability was calculated as: Cell viability % = (OD575-ODblank)/(ODctrl – ODblank) x 100%. ODctrl 
is the OD of the well containing cells only. ODblank is the OD of the blank well. 
 
Figure S4.7. Detoxification of Aβ42 aggregates by HW-155-1. N2a cells were cultured  
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with 1 µM of pre-aggregated Aβ42 in the absence/presence of HW-155-1 for 24 h. 
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Chapter 5 
Supporting information 
S5.1 Melatonin derivatives synthesis 
 
Figure 5.1 Scheme of Synthesis for melatonin derivatives 
S5.2 Cell culture and Drug Treatment 
 N2a APP cells are diluted with medium to a concentration of 2×105/ml; 3 ml was plated 
into each well. 2 ml of Trypsin was then added; it was incubated at r.t. or 37°C. When most cells 
started to float, Trypsin was decanted and 5ml of fresh, pre-warmed medium was added. The cells 
were pipetted over thirty times to ensure cell separation. A drop of medium was obtained for 
counting in a 1.5 ml tube. 10ul of trypan blue was added along with 10ul of cell medium. A 
cytometer was used for counting. The general equation that was followed is total number of cells 
of all for diagonal blocks/4 X 2 X 10000 = number of cells/ml Add proper amount of cell medium 
and fresh medium into new flask according to the ratio of dilution. Pipetting 10 times to 
homogenize cells. Seed 3ml of cells in medium into each 6 well plate. When one pipette is used 
up, mix the cells in flask before use them for next pipette. Compounds for screening are resolved 
in DMSO, and 1000 folds to the final concentration in the well. Pippet 10 µl solution, and add into 
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990 ul medium, mix evenly. 12 hr after cells plated, add compounds 400 ul compounds solution 
into 3.6 ml medium. Remove medium from the six-well.  3ml medium with 1%DMSO is added to 
well 1; in well 2, Melatonin solution of 3ml is added. In well 3, 4, 5, 6, compounds solution of 3ml 
are added.  
S5.3 Preparation of Aβ1-40 monomer.  
 Lyophilized 1-42 peptide was obtained in lyophilized form and stored at -20 °C. For each 
vial containing 2mg of protein, using syringe, add 440ul of ice cold HFIP 100% solution. Mix 
peptide and incubate at room temperature for 60minutes. Aliquot into 4 siliconized vials, each vial 
100ul, containing 450ug. And another vial 20ul for 200ug. Open lid and stay in fume hood 
overnight (around 8 hours) Open the vial under vacuum concentrator, spin for 10 minutes, assuring 
no HFIP left. Caution: do not heat peptides, concentrate at room temperature only. Freeze 
eppendorf tubes with peptide film under -80C, reconstitute in 1x PBS solution before use. Every 
time when reconstitute, aliquot tubes and flash freeze to avoid aggregation.  
 
S5.4 MTReceptor PCR  
 Add 15.375 micro liters di H2O to each PCR tube per sample. Pipette the master mix into 
the PCR tubes. Extract 1-3 micro liters of DNA and pipette into the PCR tube. Vortex the mixture 
then centrifuge the PCR tube for 1 minute at 1500 RPM. Place the centrifuged tubes in the PCR 
machine, then set temperatures and times. Follow the cycle of: Step 1: 95° 5 min Step 2: 95° 15 
seconds Step 3: 59° 30 seconds Step 4: 72° 30 seconds Step 5: Return to step 2 for 40 cycles. Step 
6: 72° for 10 minutes. Step 7: Incubate at 4° for as long as necessary. While the DNA is in the 
PCR machines, create the agarose gel. Take 50 ml of 1XTAE buffer and add .5 grams of agarose 
and mix. Microwave the solution inside the beaker for 40 seconds or until the precipitate is gone. 
Wait until cool, and remove to a noxious gas hood. After it has cooled, add 3.5 micro liters of 
ethidium bromide solution to the beaker. Take caution as ethidium bromide is a carcinogen. 
Afterwards, pour the solution into a gel preparation tray, insert the combs, and let it 
solidify.Remove the DNA samples from the PCR machine and vortex quickly. Centrifuge if there 
is condensation on the inside of the lids. Retrieve the gel preparation tray and take out the agarose 
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gel. Remove excess gel from the sides. Remove the combs. Place the tray onto the apparatus for 
the running of electricity. Make sure that the tray is covered with a thin film of the solution in the 
apparatus. Obtain 6X loading buffer. Mix it with the DNA samples at a ratio of 1:6 with 2 
microliters of buffer to 10 microliters of DNA sample. Pipette 10 microliters of DNA into the 
submersed wells made in the agarose. Add 10 microliters of the ladder that serves as a control. 
Plug in the machine and let it run for approximately 40 minutes at 80 volts. Turn off the power 
source transfer gel into the CCD imaging system.  
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